Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B14 | Q9BPX1 | 12/20 | 0.67 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.38 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | CA3 | P07451 | 1/20 | 0.35 |
| ▸ | CA6 | P23280 | 1/20 | 0.35 |
| ▸ | CA5A | P35218 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30510820 | 0.89 | HSD17B14 (0.70) | HSD17B14HSD17B1HSD17B2FFAR4GRM5 | |
| SCHEMBL23943385 | 0.89 | HSD17B14 (0.70) | HSD17B14HSD17B1HSD17B2FFAR4GRM5 | |
| SCHEMBL30510851 | 0.86 | HSD17B14 (0.67) | HSD17B14HSD17B1HSD17B2FFAR4MAP4K4 | |
| SCHEMBL23943410 | 0.86 | HSD17B14 (0.67) | HSD17B14HSD17B1HSD17B2FFAR4MAP4K4 | |
| SCHEMBL23943388 | 0.85 | HSD17B14 (0.65) | HSD17B14HSD17B1HSD17B2FFAR4 | |
| SCHEMBL30510874 | 0.85 | HSD17B14 (0.65) | HSD17B14HSD17B1HSD17B2FFAR4 | |
| SCHEMBL23943437 | 0.85 | HSD17B14 (0.65) | HSD17B14HSD17B1HSD17B2FFAR4SCN9A | |
| SCHEMBL30510884 | 0.84 | HSD17B14 (0.64) | HSD17B14HSD17B1HSD17B2 | |
| SCHEMBL23943332 | 0.84 | HSD17B14 (0.64) | HSD17B14HSD17B1HSD17B2 | |
| SCHEMBL23943430 | 0.83 | HSD17B14 (0.70) | HSD17B14HSD17B1HSD17B2FFAR4MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230150940-A1 | HSD17B13 INHIBITORS AND USES THEREOF | INIPHARM, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230150940-A1 | HSD17B13 INHIBITORS AND USES THEREOF | INIPHARM, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230150940-A1 | HSD17B13 INHIBITORS AND USES THEREOF | INIPHARM, INC. | 2023-05-18 | — | — | US | disclosed |
| WO-2021211974-A1 | HSD17B13 INHIBITORS AND USES THEREOF | INIPHARM, INC. (US) | 2021-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150940-A1 | HSD17B13 INHIBITORS AND USES THEREOF | HSD17B1, HSD17B3, HSD17B13 | HSD17B14 7/4885HSD17B1 1/4885HSD17B2 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.